Determinants of the efficacy of viro-immunotherapy: A review

被引：10

作者：

de Graaf, J. F. ^{[1
]}

Huberts, M. ^{[1
]}

Fouchier, R. A. M. ^{[1
]}

van den Hoogen, B. G. ^{[1
]}

机构：

[1] Erasmus MC, Virosci Dept, Rotterdam, Netherlands

来源：

CYTOKINE & GROWTH FACTOR REVIEWS | 2020年 / 56卷

关键词：

Oncolytic viruses; Viro-immunotherapy; Clinical parameters; PHASE-I TRIAL; HERPES-SIMPLEX-VIRUS; CONDITIONALLY-REPLICATIVE ADENOVIRUS; TARGETED ONCOLYTIC POXVIRUS; PROOF-OF-CONCEPT; CLINICAL-TRIAL; CANCER-PATIENTS; TALIMOGENE LAHERPAREPVEC; VACCINIA VIRUS; MEASLES-VIRUS;

D O I：

10.1016/j.cytogfr.2020.07.001

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Oncolytic virus immunotherapy is rapidly gaining interest in the field of immunotherapy against cancer. The minimal toxicity upon treatment and the dual activity of direct oncolysis and immune activation make therapy with oncolytic viruses (OVs) an interesting treatment modality. The safety and efficacy of several OVs have been assessed in clinical trials and, so far, the Food and Drug Administration (FDA) has approved one OV. Unfortunately, most treatments with OVs have shown suboptimal responses in clinical trials, while they appeared more promising in preclinical studies, with tumours reducing after immune cell influx. In several clinical trials with OVs, parameters such as virus replication, virus-specific antibodies, systemic immune responses, immune cell influx into tumours and tumour-specific antibodies have been studied as predictors or correlates of therapy efficacy. In this review, these studies are summarized to improve our understanding of the determinants of the efficacy of OV therapies in humans and to provide insights for future developments in the viro-immunotherapy treatment field.

引用

页码：124 / 132

页数：9

共 78 条

[51] Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma [J].

Lang, Frederick F. ;

Conrad, Charles ;

Gomez-Manzano, Candelaria ;

Yung, W. K. Alfred ;

Sawaya, Raymond ;

Weinberg, Jeffrey S. ;

Prabhu, Sujit S. ;

Rao, Ganesh ;

Fuller, Gregory N. ;

Aldape, Kenneth D. ;

Gumin, Joy ;

Vence, Luis M. ;

Wistuba, Ignacio ;

Rodriguez-Canales, Jaime ;

Villalobos, Pamela A. ;

Dirven, Clemens M. F. ;

Tejada, Sonia ;

Valle, Ricardo D. ;

Alonso, Marta M. ;

Ewald, Brett ;

Peterkin, Joanna J. ;

Tufaro, Frank ;

Fueyo, Juan .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) :1419-+

[52] A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization [J].

Laurie, SA ;

Bell, JC ;

Atkins, HL ;

Roach, J ;

Bamat, MK ;

O'Neil, JD ;

Roberts, MS ;

Groene, WS ;

Lorence, RM .

CLINICAL CANCER RESEARCH, 2006, 12 (08) :2555-2562

[53] A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients [J].

Li, J-L ;

Liu, H-L ;

Zhang, X-R ;

Xu, J-P ;

Hu, W-K ;

Liang, M. ;

Chen, S-Y ;

Hu, F. ;

Chu, D-T .

GENE THERAPY, 2009, 16 (03) :376-382

[54] Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines [J].

Lohmueller, Jason ;

Finn, Olivera J. .

PHARMACOLOGY & THERAPEUTICS, 2017, 178 :31-47

[55] A phase II study of REOLYSINA® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma [J].

Mahalingam, Devalingam ;

Fountzilas, Christos ;

Moseley, Jennifer ;

Noronha, Nicole ;

Tran, Hue ;

Chakrabarty, Romit ;

Selvaggi, Giovanni ;

Coffey, Matthew ;

Thompson, Brad ;

Sarantopoulos, John .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (04) :697-703

[56] A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses [J].

Markert, James M. ;

Razdan, Shantanu N. ;

Kuo, Hui-Chien ;

Cantor, Alan ;

Knoll, Anette ;

Karrasch, Matthias ;

Nabors, L. Burt ;

Markiewicz, Michael ;

Agee, Bonita S. ;

Coleman, Jennifer M. ;

Lakeman, Alfred D. ;

Palmer, Cheryl A. ;

Parker, Jacqueline N. ;

Whitley, Richard J. ;

Weichselbaum, Ralph R. ;

Fiveash, John B. ;

Gillespie, G. Yancey .

MOLECULAR THERAPY, 2014, 22 (05) :1048-1055

[57] Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma [J].

Mell, Loren K. ;

Brumund, Kevin T. ;

Daniels, Gregory A. ;

Advani, Sunil J. ;

Zakeri, Kaveh ;

Wright, Mary E. ;

Onyeama, Sara-Jane ;

Weisman, Robert A. ;

Sanghvi, Parag R. ;

Martin, Peter J. ;

Szalay, Aladar A. .

CLINICAL CANCER RESEARCH, 2017, 23 (19) :5696-5702

[58] REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors [J].

Morris, Don G. ;

Feng, Xiaolan ;

DiFrancesco, Lisa M. ;

Fonseca, Kevin ;

Forsyth, Peter A. ;

Paterson, Alexander H. ;

Coffey, Matt C. ;

Thompson, Brad .

INVESTIGATIONAL NEW DRUGS, 2013, 31 (03) :696-706

[59] A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer [J].

Nakao, A. ;

Kasuya, H. ;

Sahin, T. T. ;

Nomura, N. ;

Kanzaki, A. ;

Misawa, M. ;

Shirota, T. ;

Yamada, S. ;

Fujii, T. ;

Sugimoto, H. ;

Shikano, T. ;

Nomoto, S. ;

Takeda, S. ;

Kodera, Y. ;

Nishiyama, Y. .

CANCER GENE THERAPY, 2011, 18 (03) :167-175

[60] A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors [J].

Nemunaitis, John ;

Tong, Alex W. ;

Nemunaitis, Michael ;

Senzer, Neil ;

Phadke, Anagha P. ;

Bedell, Cynthia ;

Adams, Ned ;

Zhang, Yu-An ;

Maples, Phillip B. ;

Chen, Salina ;

Pappen, Beena ;

Burke, James ;

Ichimaru, Daiju ;

Urata, Yasuo ;

Fujiwara, Toshiyoshi .

MOLECULAR THERAPY, 2010, 18 (02) :429-434

← 1 2 3 4 5 6 7 8 →